更新于：2024-11-01
AvidinOx-Lu-177-DOTA-Biotin
更新于：2024-11-01
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
使用我们的XDC技术数据为新药研发加速。
登录
或
关联
2
项与 AvidinOx-Lu-177-DOTA-Biotin 相关的临床试验A Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Dosimetry, Maximum Tolerated Dose and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by Systemic IV Administration of Escalating Doses of [177Lu]DOTA-biotin in Patients With Solid Tumors or Lymphomas With Injectable Neoplastic Lesions.
Local treatment of unresectable tumors is challenging, particularly with radioactivity. Current practice relies on external beam irradiation or on a variety of medical devices for brachytherapy. Both approaches proved useful in controlling tumor growth but are characterized by poor patient's compliance, significant side effects, high costs and technological complexity hampering wide-spread use. The use of AvidinOX for radionuclide therapy of inoperable cancer lesions will offer a number of advantages compared to current brachytherapy. In fact, the perfusion of a target tissue with AvidinOX, compared to current devices, will allow adapting the therapy to the tumor/organ shape, and it will also make it possible to delay the administration of radioactivity for several days which, according to pre-clinical studies, might be also divided up into repeated doses. AvidinOX linking stably to tissue proteins, does not exhibit the problem of seed migration which is associated with high morbidity. Based on previous findings with AvidinOX in combination with radionuclides in pre-clinical studies as well as data from the clinical use in liver metastases, it can be assumed that intralesional injections of AvidinOX followed by intravenous injections of 177Lu-ST2210 could be a safe and efficacious method for treating inoperable tumor lesions.
开始日期2017-08-07 |
申办/合作机构 |
A Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Dosimetry, Maximum Tolerated Dose and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by Systemic IV Administration of Escalating Doses of [177Lu]DOTA-biotin in Patients With Liver Metastases From Colorectal Cancer
The purpose of the study is to assess a new treatment for patients with liver tumor metastases from colorectal cancer. The treatment has never been used in humans before. The treatment foresees the use of two compounds: AvdinOX and [177Lu]DOTA-biotin.
AvidinOX is a new compound, essentially a natural protein obtained from hen eggs, while [177Lu]DOTA-biotin is a new chemical compound resulting from the combination of the DOTA-biotin (also deriving from a natural vitamin which is biotin) with the 177Lutetium, an atom which emits radiation.
AvidinOX will be injected directly into the metastases in the liver and [177Lu]DOTA-biotin will be injected into the arm vein.
One specific property of AvidinOX is that it chemically links to the tumor tissues when it is injected while maintaining the capacity to take up [177Lu]DOTA-biotin. Once locally bound in tumor tissue, AvidinOX becomes an "artificial receptor" for intravenously injected [177Lu]DOTA-biotin, which allows an internal radiation therapy of the tumor tissue.
The treatment of liver metastases with local injection of AvidinOX and the following intra-venous injection of [177Lu]DOTA-biotin could be simpler and more tolerable than the current available treatments.
AvidinOX is a new compound, essentially a natural protein obtained from hen eggs, while [177Lu]DOTA-biotin is a new chemical compound resulting from the combination of the DOTA-biotin (also deriving from a natural vitamin which is biotin) with the 177Lutetium, an atom which emits radiation.
AvidinOX will be injected directly into the metastases in the liver and [177Lu]DOTA-biotin will be injected into the arm vein.
One specific property of AvidinOX is that it chemically links to the tumor tissues when it is injected while maintaining the capacity to take up [177Lu]DOTA-biotin. Once locally bound in tumor tissue, AvidinOX becomes an "artificial receptor" for intravenously injected [177Lu]DOTA-biotin, which allows an internal radiation therapy of the tumor tissue.
The treatment of liver metastases with local injection of AvidinOX and the following intra-venous injection of [177Lu]DOTA-biotin could be simpler and more tolerable than the current available treatments.
开始日期2013-11-11 |
申办/合作机构 |
100 项与 AvidinOx-Lu-177-DOTA-Biotin 相关的临床结果
登录后查看更多信息
100 项与 AvidinOx-Lu-177-DOTA-Biotin 相关的转化医学
登录后查看更多信息
100 项与 AvidinOx-Lu-177-DOTA-Biotin 相关的专利（医药）
登录后查看更多信息
24
项与 AvidinOx-Lu-177-DOTA-Biotin 相关的文献（医药）2021-12-30·Urologiia
The use of rectal suppositories with oxidised dextran for calculous prostatitis
Article
作者: Novikova, E G ; Troitsky, A V ; Ukah, H U
2021-10-01·European Journal of Nuclear Medicine and Molecular Imaging1区 · 医学
Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms
1区 · 医学
Article
作者: Wadas, Thaddeus J ; Strosberg, Jonathan R ; Wang, Zhen ; El-Haddad, Ghassan ; Engelman, Robert W ; Pandya, Darpan N ; Morse, David L ; Reff, Jordan N ; Tafreshi, Narges K ; Ji, Haitao ; Budzevich, Mikalai M ; Tichacek, Christopher J ; Boulware, David C ; Chiappori, Alberto A
2018-11-01·Bioorganic & Medicinal Chemistry Letters4区 · 医学
Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative
4区 · 医学
Article
作者: Dallavalle, Sabrina ; Minenkova, Olga ; Vesci, Loredana ; Santapaola, Daniela ; Musso, Loana ; Cincinelli, Raffaella ; De Santis, Rita ; Giannini, Giuseppe
3
项与 AvidinOx-Lu-177-DOTA-Biotin 相关的新闻（医药）2024-06-01
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL. The published abstract titled “Preclinical characterization of pretargeted radioimmunotherapy with GD2-SADA, a self-assembling and disassembling bispecific fusion protein” characterizes the binding properties of GD2-SADA across several GD2-expressing cell lines and lanthanide metal-DOTA complexes, while also demonstrating its anti-tumor efficacy when used with Lutetium 177 (Lu177)-DOTA in a two-step approach to pretargeted radioimmunotherapy (“PRIT”). In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors. GD2-SADA binding was significantly improved by a p53-derived domain that drives the self-assembly and disassembly (“SADA”) of GD2-SADA tetramers, which possess four distinct GD2-binding domains that cumulatively enhance binding. Previous studies have shown that the unbound GD2-SADA protein disassembles over time, facilitating clearance by the kidneys. “We believe that these data further validate GD2-SADA's promise as a novel targeted radioimmunotherapy and support the continued advancement of our SADA PRIT technology platform and clinical programs,” said Vignesh Rajah, MBBS, DCH, MRCP (UK), Chief Medical Officer. The analysis further demonstrated high-affinity binding of GD2-SADA to DOTA complexes chelated with lutetium and lanthanum, among other lanthanide metals. By contrast, GD2-SADA showed negligible binding to trace metal-DOTA complexes or empty DOTA, an important consideration for the targeted delivery of the radioactive payload in patients. “We are especially encouraged by the selective binding of GD2-SADA to lanthanide metal-DOTA complexes with current and emerging applications in the diagnosis and targeted treatment of solid tumors,” said Brian H. Santich, Ph.D., the lead author and co-inventor of the SADA PRIT technology platform. Taken together, the binding properties of the GD2-SADA protein provide a pharmacological basis for the robust and dose-responsive anti-tumor effects of GD2-SADA Lu177 PRIT in vivo, also presented in this seminal research. These findings have paved the way for the clinical development of GD2-SADA PRIT in adults and adolescents with GD2-positive tumors (NCT05130255). Y-mAbs will be available for comment at booth #35151 on the Exhibition Floor of McCormick Place. Researchers at MSK, including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2023 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans, including potential partnerships; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA Technology and potential benefits and applications thereof; statements with respect to DANYELZA as a growing commercial product and SADA as a differentiated radioimmunotherapy platform positioning the Company on a path to potentially transform the treatment paradigm for a variety of cancers and improve patients’ lives; expectations relating to key anticipated development milestones, including potential expansion of international commercialization efforts with respect to DANYELZA development efforts and the SADA Technology, including potential indications and applications, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations related to the timing of the initiation and completion of regulatory submissions; additional product candidates and technologies; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. Investor Contact:Courtney DuganVP, Head of Investor Relationscdu@ymabs.com
免疫疗法引进/卖出ASCO会议上市批准临床研究
2024-03-14
DUBLIN, March 13, 2024 /PRNewswire/ -- The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to
ResearchAndMarkets.com's offering.
Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2024.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:
Understand royalty rate trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Browse collaboration and licensing deals which reveal a royalty rate
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharmaceuticals and biotechnology
1.4. Royalties versus revenue share
1.5. Overview of the report
Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates
2.1. Trends in royalty rates 2010 - 2024
2.2. How do revenue shares figure?
2.3. A review of recent literature
2.4. Royalty rates in the future
Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals
3.1. Partnering agreement structure
3.2. Structure of a typical royalty clause
3.3. Example royalty clauses
3.3.1. Case study 1
3.3.2. Case study 2
3.3.3. Case study 3
3.3.4. Case study 4
Chapter 4 - Companies actively disclosing royalty rates
4.1. Most active companies in disclosing royalty rates
Chapter 5 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight
Deal directory
Deal Directory - Royalty rates in deals - by company A-Z
Deal Directory - Royalty rates in deals - by therapy area
Deal Directory - Royalty rates in deals - by stage of development at signing
Deal Directory - Royalty rates in deals - by technology type
Royalty rate references
Example royalty rate deal contract document
List of Figures
Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
Figure 2: Components of the partnering deal structure
Figure 3: Components of the partnering royalty clause
Figure 4: Most active companies disclosing royalty rate 2010 - 2024
Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies
Companies Mentioned
2seventy bio
3a-diagnostics
3D Medicines
4SC
23andMe
Abbott Laboratories
Abbvie
Abeona Therapeutics
Ablynx
Abraxis BioScience
ABVC BioPharma
ACADIA Pharmaceuticals
Acceleron Pharma
Acelrx Pharmaceuticals
Acer Therapeutics
Acerus
Acrotech Biopharma
Actavis (acquired by Watson)
Active Biomaterials
Acura Pharmaceuticals
Adamis Pharmaceuticals
Adaptimmune
ADC Therapeutics
Adeona Pharmaceuticals
Adial Pharmaceuticals
Aditx Therapeutics
Adlai Nortye
Aduro BioTech
Advanced Dosage Forms
Advanz Pharma
Advaxis
Advirna
Aegerion Pharmaceutical
Aeglea BioTherapeutics
Aerie Pharmaceuticals
AEterna Zentaris
Aexon Labs
Affimed Therapeutics
Afritex Medical Products
AFT Pharmaceuticals
Agenus Bio
Agios Pharmaceuticals
Aguettant
AiBtl BioPharma
AIT Therapeutics
Akcea Therapeutics
Akebia Therapeutics
Albert Einstein College of Medicine
Alchemia
Alder Biopharmaceuticals
Alector
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alfasigma
Alfa Wassermann
Allergan
Allergan (name changed from Actavis)
Almirall
Alnylam Pharmaceuticals
Alora Pharmaceuticals
Alpha Biopharma
Alternavida
Altman Enterprises
AltrazealTrading
Altum Pharmaceuticals
Alvogen
Amarantus BioSciences
American Type Culture Collection (ATCC)
Amgen
Amherst Pharmaceuticals
Amorfix Life Sciences
Ampio Pharmaceuticals
Amryt Pharma
Amylin Pharmaceuticals
Amyris
AnaBios
AnaptysBio
AnGes MG
Angion Biomedica
AnnaMed
Antares Pharma
Antibe Therapeutics
Antigen Express
Applied Therapeutics
Apricus Biosciences
Aquestive Therapeutics
Aradigm
Aratana Therapeutics
Arcellx
Arch Pharmalabs
Arctic Vision
Arcturus Therapeutics
Arcus Biosciences
Ardelyx
Arena Pharmaceuticals
Arrowhead Pharmaceuticals
Artiva Biotherapeutics
Arvinas
Ascendis Pharma
Ascentage Pharma
Ashvattha Therapeutics
Assembly Biosciences
Astellas Pharma
Astellas Pharma Europe
Asterias Biotherapeutics
AstraZeneca
Athenex
Atossa Therapeutics
Atreca
Audeo Oncology
Augmenta
Aurigene Discovery Technologies
Aurinia Pharmaceuticals
Authentic Brands Group
AVEO Oncology
Avita Therapeutics
Avivagen
Axovant Gene Therapies
Axsome Therapeutics
Aytu BioPharma
Azaya Therapeutics
Azure Biotech
Baker Brothers Investments
BAKX Therapeutics
Baliopharm
BASF
Baxter International
Bayer Healthcare
Bayer Innovation
Baylor Research Institute
Beam Therapeutics
BeiGene
Beijing Defengrei Biotechnology
Belgian Volition
Bellerophon Therapeutics
Benitec Biopharma
Besins Healthcare
Beth Israel Deaconess Medical Center
BetterLife Pharma
Bharat Biotech
BIND Biosciences
BioCorRx
BioCryst Pharmaceuticals
Bioeq IP
Biogen
BioGene Technology
Biohaven Pharmaceuticals
BioInvent
BiolineRX
BioMarin Pharmaceutical
BioNovion
BioNTech
BioNxt Solutions
Biopharmex
BiopharmX
BioPorto
Bioprocess Capital Ventures
BioProspect
Biostem US
Biotech Investment
Biotechnology Value Fund
BioTime Acquisition
Bioton
Biovail
BioZone Laboratories
BioZone Pharmaceuticals
Blackstone
Bluebird Bio
Blueprint Medicines
BMV Medica
Boehringer Ingelheim
Bone Therapeutics
Braeburn Pharmaceuticals
BrainStorm Cell Therapeutics
Breathtec BioMedical
Brickell Biotech
BridgeBio Pharma
Bridge Biotherapeutics
Bristol-Myers Squibb
Caleco Pharma
Calico
Can-Fite BioPharma
Cancer Prevention Pharmaceuticals
Cannassure Therapeutics
CanniMed Therapeutics
Cann Pharmaceutical Australia
Canntab Therapeutics
Cannus Partners
Cantex Pharmaceuticals
Cara Therapeutics
Cardigant Medical
Cardium Therapeutics
CareFusion
Carna BioSciences
Cary Pharmaceuticals
CASI Pharmaceuticals
Castle Creek Biosciences
Catalent
CB2 Therapeutics
Celdara Medical
Celgene
Cell Cure Neurosciences
Cellvera
Cel Sci
Celyad
Cereal Ingredients
Cerebain Biotech
Cerus
CGA 369
cGreen
Chi-Med
Chiesi Farmaceutici
Chimerix
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Cimtech
Cipher Pharmaceuticals
Cipla
Circassia
Clal Biotech
Clalit Health Services
Clearmind Medicine
Clearside Biomedical
Clemson University
Cleveland BioLabs
Clinigen
CMIC
CNS Pharmaceuticals
Cocrystal Pharma
Coeptis Pharmaceuticals
CohBar
Cohen-McNiece Foundation
Coherus Biosciences
Colby Pharmaceuticals
Collegium Pharmaceuticals
Columbia Laboratories
Columbia University
Common Sense
Conatus Pharmaceuticals
Concile
Consilient Health
ContraFect
Coronado Biosciences
Cosmofix
Cosmo Pharmaceuticals
Coya Therapeutics
CRISPR Therapeutics
Crossject
Crucell
CSL
CTI BioPharma
CTT Pharmaceutical
Cullinan Oncology
Cumberland Pharmaceuticals
Cures Within Reach
CureTech
Curis
Currax Pharmaceuticals
CURx Pharmaceuticals
Cutanea Life Sciences
Cybin
CymaBay Therapeutics
Cypress Bioscience
Cytodyn
Cytokinetics
Cytori Therapeutics
Daewoong Pharmaceutical
Daiichi Sankyo
Dana-Farber Cancer Institute
Dance Biopharm
DAS Therapeutics
Defiante Farmaceutica
Denali Therapeutics
DepoMed
Derma Sciences
Dermavant Sciences
Dermin
Dianomi Therapeutics
Dicerna Pharmaceuticals
DNA Biomedical Solutions
Dr. Falk Pharma
Dr. Reddy's Laboratories
Dragonfly Therapeutics
DRI Capital
Drugs for Neglected Diseases Initiative
DS Healthcare
Duke University
Dyax
Eagle Pharmaceuticals
Eagle Pharmaceuticals (US)
Easton Pharmaceuticals
Echo Therapeutics
Ecology Coatings
Eczacibasi Pharmaceuticals
Eddingpharm
Egalet
Eisai
Elencee
Eli Lilly
Elite Pharmaceuticals
Emergent BioSolutions
Emory University
Enalare Therapeutics
Endocyte
Endo Pharmaceuticals
EnGeneIC
Enochian Biosciences
Entera Bio
Entest BioMedical
EnWave
Epizyme
Epocal
Esperion Therapeutics
Eternity Healthcare
Eton Pharmaceuticals
Eureka Genomics
EUSA Pharma
Evolva
Ewopharma
Exact Sciences
Exelixis
ExScientia
Eyevance
Fairview Health System
FasTrack Pharmaceuticals
Ferozsons Laboratories
Ferring Pharmaceuticals
Fibrocell Science
Foghorn Therapeutics
Forest Laboratories
Fosun Pharmaceutical
Fox Chase Chemical Diversity Center
Fresenius Kabi Pharmaceuticals
FSD Pharma
Fusion Pharmaceuticals
FusionVax
Galapagos
Galmed Pharmaceuticals
GE Healthcare
Genentech
Generex Biotechnology
Genevant Sciences
Genexine
Genfit
Genmab
Gentium
Genzyme
Geron
Gilead Sciences
Glaukos
Glenmark Generics Inc USA
Glenmark Pharmaceuticals
Goldfinch Bio
Government of Israel
GPCR Therapeutics
Gravocore
Grifols
GSK
GT Biopharma
Hai Kang Life
Hail First Pharma
Hainan Sihuan Pharmaceutical
Halo Labs
Halozyme Therapeutics
Hansen Medical
Health Canada
Healthcare Royalty Partners
Health Discovery
Heartseed
Heat Biologics
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HekaBio
Helsinn Therapeutics
HemoCleanse
Hemogenyx
HemPup
Henlius Biotech
Hetero Labs
HIBM Research Group
Hikma Pharmaceuticals
Hoffmann La Roche
Hollister Biosciences
Hookipa Pharma
Horizon Pharma Inc
Huadong Medicine
HyperGenomics
I-mab
Icahn School of Medicine at Mount Sinai
Ice + Jam
Iconovo
IDC-GP Pharm
IDEAYA Biosciences
Idera Pharmaceuticals
Idorsia
Idun Pharmaceuticals
IGM Biosciences
iMetabolic Biopharma
Immugenyx
Immunic
ImmunityBio
Immunomedics
Immunomic Therapeutics
Immunovative Therapies
ImmVira
Impax Laboratories
Imprimis Pharmaceuticals
In4Derm
iNAP
Incannex Healthcare
Incuron
Incyte
Indiana University
Infinity Pharmaceuticals
InflaRx
Inhibitor Therapeutics
Innate Pharma
Innocoll
Innovate Biopharmaceuticals
Innovation Pharmaceuticals
Innovent Biologics
Innovet
Innovus Pharmaceuticals
INO Therapeutics
Inspiration Biopharmaceuticals
Instrumentation Laboratory
IntelGenx
Intellia Therapeutics
IntelliCell BioSciences
Intellikine
Internet Marketing Consortium
Intrexon
Intuitive Surgical
Invekra
Inverness Medical Innovations
Ionis Pharmaceuticals
Ipsen
Iroko Pharmaceuticals
Ironwood Pharmaceuticals
Israeli National Authority for Technological Innovation
Itrom Pharmaceutical Group
Ivantis
Jaguar Health
Janssen Biotech
Janssen Pharmaceuticals
Jazz Pharmaceuticals
JFC Technologies
Jiangsu Alphamab
Jiangsu Lianhuan Pharmaceuticals
Jiangsu NHWA Pharmaceutical
Ji Xing Pharmaceuticals
John Morley Foods
Joincare Pharmaceutical
Journey Medical
Jubilant Life Sciences
Jumpcan Pharmaceutical
Juniper Pharmaceuticals
Junshi Biosciences
Jupiter Wellness
Juventas Therapeutics
K2M
Kadmon Pharmaceuticals
Kaken Pharmaceutical
Kalbe Genexine Biologics
KaloBios Pharmaceuticals
Karveer Meditech
KemPharm
Kensey Nash
Kieran Murphy
Kinetic Concepts
Kiniksa Pharmaceuticals
Kintor
Kiromic Biopharma
Kite Pharma
Kitov Pharma
Klaria
Klinge Biopharma
Knighton Foods
Knight Therapeutics
Kodiak Sciences
Kowa
Kraig Biocraft Laboratories
KVK-Tech
Kwang Dong Pharmaceutical
Kymera Therapeutics
Kyowa Hakko Kirin
Kyverna Therapeutics
L1 Systems
Laboratories Acbel
Lantheus Holding
Launch Therapeutics
Lee Moffitt Cancer Center
Legend Biotech
LegoChem Biosciences
Level Brands
LFB Biotechnologies
Lifestyle Delivery Systems
Ligand Pharmaceuticals
Lineage Cell Therapeutics
Link Health
Lipidor
Lipocine
Lixte Biotechnology
Lorna Linda University
Lotus Pharmaceuticals
Loxo Oncology
Lubrizol
Lumenis
Lundbeck
Lung Therapeutics
MabCure
Macrogenics
Magenta Therapeutics
MainPointe
Mallinckrodt Pharmaceuticals
Marvanal
Marv Enterprises
Massachusetts General Hospital
Matrix Biomed
Mayne Pharma
McComb Foundation
McEwen Centre for Regenerative Medicine
Meda
Medica
Medica Avante
Medical Technologies Innovation Asia
Medice Arzneimittel Putter
Medicines Patent Pool Foundation
Medicox
MediGene
Medigus
MedImmune
Medison Pharma
Medivation
Medivir
Medovex
MEI Pharma
Melmed
Memory Dx
Mercer University
Merck and Co
Merck KGaA
Merck Serono
Merus
Methodist Hospital Houston
Micromet
Mikah Pharma
Millennium
Mimi's Rock
Mindset Pharma
Ministry of Health
Labor and Welfare
MiNK Therapeutics
Miraculins
Miralogx
Mira Pharmaceuticals
Miromatrix Medical
Mitsubishi Tanabe Pharma
Moderna
Modis Therapeutics
Moleculin Biotech
Mologen
Momenta Pharmaceuticals
Monash University
Monopar Therapeutics
Morgan Stanley
MorphoSys
Mount Sinai Health System
MultiCell Immunotherapeutics
Munich Leukemia Laboratory
Mylan Laboratories
Mylan Pharmaceuticals
Myovant Sciences
NanoVibronix
NanoViricides
NantCell
NantKwest
Nantong Jinghua Pharmaceutical
NantWorks
Napo Pharmaceuticals
Natac Biotech
Natco Pharmaceuticals
National Green Biomed
Nektar Therapeutics
Neogenomics
Neotope
Nephrogenex
Nephros
Nestle Health Science
Neuraxpharm
Neurocrine Biosciences
NeuroRx
NeuroSigma
NeuroVive Pharmaceutical
NeuroVive Pharmaceutical Asia
NewLeaf Brands
Newsoara Biopharma
New York University
NexMed
NextCure
Nextleaf Solutions
Nexvet
NGM Biopharmaceuticals
Nicox
Nkarta Therapeutics
NLS Pharmaceutics
Nordic Bioscience
Norgine
NorthStar Medical Radioisotopes
Notable Labs
Novadaq Technologies
NovaDel Pharma
Novan
Novan Therapeutics
Novartis
Novartis Vaccines and Diagnostics
Novocure
Novo Nordisk
Novus Biologicals
NRx Pharmaceuticals
Nucorion
Numab
Nunzi Pharmaceutical
Nurix Therapeutics
Nutech Medical
NutraOrigin
NXTGEN
Nymox Pharmaceutical
Oberland Capital
Ocugen
Oculus Innovative Sciences
Ocumension Therapeutics
Omeros
Oncologie
Oncolytics Biotech
OncoMed Pharmaceuticals
Onconova Therapeutics
Onegevity
One Way Liver Genomics (OWL)
ONK Therapeutics
Ono Pharmaceutical
Onxeo
Onyx Pharmaceuticals
Opexa Therapeutics
Opthea
OptiBiotix
OptiNose
Oragenics
Oramed Pharmaceuticals
Orexigen Therapeutics
Organovo
Orgenesis
Orion
Orox Pharmaceuticals
OrthoCyte
Otsuka
OvaMed
Ovid Therapeutics
Oxford BioMedica
Oxis Biotech
Oxygen Biotherapeutics
OxySure Systems
Oyster Point Pharma
Pan-Provincial Vaccine Enterprise
Parnell Pharmaceuticals
Par Pharmaceutical
PDL BioPharma
PDS Biotechnology
Penwest Pharmaceuticals
Pernix Therapeutics
Perugia University
Pfenex
Pfizer
Pharmacyclics
PharmaCyte Biotech
PharmaMar
PharmaNova
Pharmastrip
Philogen
Phosphagenics
Photocure ASA
Phusion Laboratoies
Phyto Nutricare
Pipex Pharmaceuticals
Plandai Biotechnology
Pluristem Therapeutics
POINT Biopharma
Portola Pharmaceuticals
Poseida Therapeutics
Pozen
PreMD
Premier Biomedical
Professional Compounding Centers of America
Progenics Pharmaceuticals
Prometic Life Sciences
ProQR Therapeutics
Prosidion
Protagonist Therapeutics
Protalix BioTherapeutics
Proteonomix
Prothena
ProtoKinetix
Pulmatrix
Puma Biotechnology
QED Therapeutics
QRxPharma
Quick Med Technologies
Quigley Corporation
Quoin Pharmaceuticals
Rayner Surgical
Reata Pharmaceuticals
Recordati
Recro Pharma
RedHill Biopharma
Reedy Creek Investments
RegenaStem
Regeneron Pharmaceuticals
Regenxbio
Regnum
Relay Therapeutics
Relief Therapeutics
Relmada Therapeutics
RenalytixAI
ReNeuron
Repare Therapeutics
Replicel Life Sciences
Repligen
Reprise Biomedical
Resarci Therapeutics
Retrophin
rEVO Biologics
Revolution Medicines
Rigel Pharmaceuticals
RNL Bio
Roche
Rockefeller University
Roivant Sciences
Royalty Pharma
RST Biomedikal Sanayi
Ruthigen
RXi Pharmaceuticals
S2 Therapeutics
SACCO
Sagard Healthcare Royalty Partners
Sage Therapeutics
Salix Pharmaceuticals
Sam Amer
Sanara MedTech
Sandoz
Sanofi
Sanofi-Aventis
Sanofi-Pasteur
Sanpellegrino Cosmetics
Santarus
Santen Pharmaceutical
Sanuwave Health
SA Pathology
Sapientia Pharmaceuticals
Sarepta Therapeutics
Schrodinger
Scopus BioPharma
Seagen
Seattle Genetics
Seelos Therapeutics
Sekris Biomedical
Senetek
Senior Paradise
Sensory Cloud
Seqirus
Seres Therapeutics
Sermonix Pharmaceutical
Sesen Bio
SevenScore Pharmaceuticals
Shanghai Pharmaceuticals Holdings
Sheba Medical Center
Shenzhen BioScien Pharmaceuticals
Shield Therapeutics
Shionogi
Shire Pharmaceuticals
Shore Therapeutics
Siemens Healthcare Diagnostics
Sigma-Tau
Sinclair Pharmaceuticals
Sinobiopharma
Sinopharm
Sio Gene Therapies
Skinvera
Skyline Diagnostics
Solarvest BioEnergy
Soliance
Soligenix
Sonoma BioTherapeutics
Sorrento Therapeutics
Spectranetics
Spencer Pharmaceutical
Spinal USA
St. Jude Children's Research Hospital
STADA Arzneimittel
Staidson (Beijing) BioPharmaceuticals
Stanford University
Stealth BioTherapeutics
Stellar Biotechnologies
St Jude Medical
Stoke Therapeutics
Strongbridge Biopharma
Sucampo AG
SUDA Pharmaceuticals
Sumitomo Dainippon Pharma
Sunesis Pharmaceuticals
Sunovion Pharmaceuticals
Sun Pharmaceutical
SuperNova Diagnostics
Sutro Biopharma
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbollon
Syndax Pharmaceuticals
Synergy Strips
Syntopix
Tactical Relief
Taiba
TaiGen Biotechnology
Taiho
Takeda Pharmaceutical
Talaris Therapeutics
Tango Therapeutics
Target Group
Tauriga Sciences
TB Alliance
TearLab
Technion Research and Development Foundation
Teijin
Telomir Pharmaceuticals
Tesaro
Tetra Bio-Pharma
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
Texas A&M University
Texas Heart Institute
TFF Pharmaceuticals
TG Therapeutics
Therakine
TherapeuticsMD
Theravance
Theravance Biopharma
The Regents of the University of California
Thorne Research
Threshold Pharmaceuticals
TiGenix
Tilray
Titterington Veterinary Services
Tiziana Life Sciences
Tocagen
TONIX Pharmaceuticals
Torii Pharmaceutical
TRACON Pharmaceuticals
Tramorgan
Transgene
Travere Therapeutics
Trellis Bioscience
Trevena
Trimedyne
Trimeris
TrovaGene
TTFactor
Tufts University
Turnstone Biologics
Tyme Technologies
Ultragenyx Pharmaceuticals
Uluru
Unigene Laboratories
UniQure
Universal Cells
University College Dublin
University Health Network
University of Alberta
University of California
University of Central Florida Research Foundation
University of Colorado
University of Florida Research Foundation
University of Geneva
University of Louisville
University of Missouri
University of Notre of Dame
University of Pennsylvania
University of Texas
University of Virginia
University of Western Sydney
University of Zurich
UOP
Uppsalagruppen Medical
Upstream Peripheral Technologies
UroGen Pharma
Valeant Pharmaceuticals
ValiPharma
Valneva
Valor Biotherapeutics
Vanderbilt University
Vasomune Therapeutics
Vaxent
VBL Therapeutics
Veloxis Pharmaceuticals
Veracyte
Verenium
Verity Pharmaceuticals
VeroScience
Vertex Pharmaceuticals
Vida Concepts
Vifor Pharma
ViiV Healthcare
Virbac
Viropharma
VistaGen Therapeutics
Vividion Therapeutics
Vivus
VolitionRX
Voronoi
Voyager Therapeutics
Vyera Pharmaceuticals
VYNE Therapeutics
Vyrix Pharmaceuticals
Watson Pharmaceuticals
WAVE Life Sciences
Wigen Biomedicine
Wisconsin Alumni Research Foundation
World Class Extractions
WPD Pharmaceuticals
WUGEN
Xbrane Bioscience
Xencor
Xlife Sciences
XPhyto Therapeutics
XTL Biopharmaceuticals
Xynomic Pharmaceuticals
Yale University
Yeda Research and Development Company
Yeugnam University
Yissum Research Development
ZAI Laboratory
Zalicus
Zenitech
Zenith Epigenetics
Ziopharm Oncology
Zogenix
ZS Pharma
Zymeworks
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
疫苗并购
2024-03-13
DUBLIN--(
BUSINESS WIRE
)--The
"Royalty Rates in Pharmaceutical and Biotechnology Deals"
report has been added to
ResearchAndMarkets.com's
offering.
Royalty Rates in Pharmaceutical and Biotechnology Deals
is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2024.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:
Understand royalty rate trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Browse collaboration and licensing deals which reveal a royalty rate
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharmaceuticals and biotechnology
1.4. Royalties versus revenue share
1.5. Overview of the report
Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates
2.1. Trends in royalty rates 2010 - 2024
2.2. How do revenue shares figure?
2.3. A review of recent literature
2.4. Royalty rates in the future
Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals
3.1. Partnering agreement structure
3.2. Structure of a typical royalty clause
3.3. Example royalty clauses
3.3.1. Case study 1
3.3.2. Case study 2
3.3.3. Case study 3
3.3.4. Case study 4
Chapter 4 - Companies actively disclosing royalty rates
4.1. Most active companies in disclosing royalty rates
Chapter 5 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight
Deal directory
Deal Directory - Royalty rates in deals - by company A-Z
Deal Directory - Royalty rates in deals - by therapy area
Deal Directory - Royalty rates in deals - by stage of development at signing
Deal Directory - Royalty rates in deals - by technology type
Royalty rate references
Example royalty rate deal contract document
List of Figures
Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
Figure 2: Components of the partnering deal structure
Figure 3: Components of the partnering royalty clause
Figure 4: Most active companies disclosing royalty rate 2010 - 2024
Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies
Companies Mentioned
2seventy bio
3a-diagnostics
3D Medicines
4SC
23andMe
Abbott Laboratories
Abbvie
Abeona Therapeutics
Ablynx
Abraxis BioScience
ABVC BioPharma
ACADIA Pharmaceuticals
Acceleron Pharma
Acelrx Pharmaceuticals
Acer Therapeutics
Acerus
Acrotech Biopharma
Actavis (acquired by Watson)
Active Biomaterials
Acura Pharmaceuticals
Adamis Pharmaceuticals
Adaptimmune
ADC Therapeutics
Adeona Pharmaceuticals
Adial Pharmaceuticals
Aditx Therapeutics
Adlai Nortye
Aduro BioTech
Advanced Dosage Forms
Advanz Pharma
Advaxis
Advirna
Aegerion Pharmaceutical
Aeglea BioTherapeutics
Aerie Pharmaceuticals
AEterna Zentaris
Aexon Labs
Affimed Therapeutics
Afritex Medical Products
AFT Pharmaceuticals
Agenus Bio
Agios Pharmaceuticals
Aguettant
AiBtl BioPharma
AIT Therapeutics
Akcea Therapeutics
Akebia Therapeutics
Albert Einstein College of Medicine
Alchemia
Alder Biopharmaceuticals
Alector
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alfasigma
Alfa Wassermann
Allergan
Allergan (name changed from Actavis)
Almirall
Alnylam Pharmaceuticals
Alora Pharmaceuticals
Alpha Biopharma
Alternavida
Altman Enterprises
AltrazealTrading
Altum Pharmaceuticals
Alvogen
Amarantus BioSciences
American Type Culture Collection (ATCC)
Amgen
Amherst Pharmaceuticals
Amorfix Life Sciences
Ampio Pharmaceuticals
Amryt Pharma
Amylin Pharmaceuticals
Amyris
AnaBios
AnaptysBio
AnGes MG
Angion Biomedica
AnnaMed
Antares Pharma
Antibe Therapeutics
Antigen Express
Applied Therapeutics
Apricus Biosciences
Aquestive Therapeutics
Aradigm
Aratana Therapeutics
Arcellx
Arch Pharmalabs
Arctic Vision
Arcturus Therapeutics
Arcus Biosciences
Ardelyx
Arena Pharmaceuticals
Arrowhead Pharmaceuticals
Artiva Biotherapeutics
Arvinas
Ascendis Pharma
Ascentage Pharma
Ashvattha Therapeutics
Assembly Biosciences
Astellas Pharma
Astellas Pharma Europe
Asterias Biotherapeutics
AstraZeneca
Athenex
Atossa Therapeutics
Atreca
Audeo Oncology
Augmenta
Aurigene Discovery Technologies
Aurinia Pharmaceuticals
Authentic Brands Group
AVEO Oncology
Avita Therapeutics
Avivagen
Axovant Gene Therapies
Axsome Therapeutics
Aytu BioPharma
Azaya Therapeutics
Azure Biotech
Baker Brothers Investments
BAKX Therapeutics
Baliopharm
BASF
Baxter International
Bayer Healthcare
Bayer Innovation
Baylor Research Institute
Beam Therapeutics
BeiGene
Beijing Defengrei Biotechnology
Belgian Volition
Bellerophon Therapeutics
Benitec Biopharma
Besins Healthcare
Beth Israel Deaconess Medical Center
BetterLife Pharma
Bharat Biotech
BIND Biosciences
BioCorRx
BioCryst Pharmaceuticals
Bioeq IP
Biogen
BioGene Technology
Biohaven Pharmaceuticals
BioInvent
BiolineRX
BioMarin Pharmaceutical
BioNovion
BioNTech
BioNxt Solutions
Biopharmex
BiopharmX
BioPorto
Bioprocess Capital Ventures
BioProspect
Biostem US
Biotech Investment
Biotechnology Value Fund
BioTime Acquisition
Bioton
Biovail
BioZone Laboratories
BioZone Pharmaceuticals
Blackstone
Bluebird Bio
Blueprint Medicines
BMV Medica
Boehringer Ingelheim
Bone Therapeutics
Braeburn Pharmaceuticals
BrainStorm Cell Therapeutics
Breathtec BioMedical
Brickell Biotech
BridgeBio Pharma
Bridge Biotherapeutics
Bristol-Myers Squibb
Caleco Pharma
Calico
Can-Fite BioPharma
Cancer Prevention Pharmaceuticals
Cannassure Therapeutics
CanniMed Therapeutics
Cann Pharmaceutical Australia
Canntab Therapeutics
Cannus Partners
Cantex Pharmaceuticals
Cara Therapeutics
Cardigant Medical
Cardium Therapeutics
CareFusion
Carna BioSciences
Cary Pharmaceuticals
CASI Pharmaceuticals
Castle Creek Biosciences
Catalent
CB2 Therapeutics
Celdara Medical
Celgene
Cell Cure Neurosciences
Cellvera
Cel Sci
Celyad
Cereal Ingredients
Cerebain Biotech
Cerus
CGA 369
cGreen
Chi-Med
Chiesi Farmaceutici
Chimerix
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Cimtech
Cipher Pharmaceuticals
Cipla
Circassia
Clal Biotech
Clalit Health Services
Clearmind Medicine
Clearside Biomedical
Clemson University
Cleveland BioLabs
Clinigen
CMIC
CNS Pharmaceuticals
Cocrystal Pharma
Coeptis Pharmaceuticals
CohBar
Cohen-McNiece Foundation
Coherus Biosciences
Colby Pharmaceuticals
Collegium Pharmaceuticals
Columbia Laboratories
Columbia University
Common Sense
Conatus Pharmaceuticals
Concile
Consilient Health
ContraFect
Coronado Biosciences
Cosmofix
Cosmo Pharmaceuticals
Coya Therapeutics
CRISPR Therapeutics
Crossject
Crucell
CSL
CTI BioPharma
CTT Pharmaceutical
Cullinan Oncology
Cumberland Pharmaceuticals
Cures Within Reach
CureTech
Curis
Currax Pharmaceuticals
CURx Pharmaceuticals
Cutanea Life Sciences
Cybin
CymaBay Therapeutics
Cypress Bioscience
Cytodyn
Cytokinetics
Cytori Therapeutics
Daewoong Pharmaceutical
Daiichi Sankyo
Dana-Farber Cancer Institute
Dance Biopharm
DAS Therapeutics
Defiante Farmaceutica
Denali Therapeutics
DepoMed
Derma Sciences
Dermavant Sciences
Dermin
Dianomi Therapeutics
Dicerna Pharmaceuticals
DNA Biomedical Solutions
Dr. Falk Pharma
Dr. Reddy's Laboratories
Dragonfly Therapeutics
DRI Capital
Drugs for Neglected Diseases Initiative
DS Healthcare
Duke University
Dyax
Eagle Pharmaceuticals
Eagle Pharmaceuticals (US)
Easton Pharmaceuticals
Echo Therapeutics
Ecology Coatings
Eczacibasi Pharmaceuticals
Eddingpharm
Egalet
Eisai
Elencee
Eli Lilly
Elite Pharmaceuticals
Emergent BioSolutions
Emory University
Enalare Therapeutics
Endocyte
Endo Pharmaceuticals
EnGeneIC
Enochian Biosciences
Entera Bio
Entest BioMedical
EnWave
Epizyme
Epocal
Esperion Therapeutics
Eternity Healthcare
Eton Pharmaceuticals
Eureka Genomics
EUSA Pharma
Evolva
Ewopharma
Exact Sciences
Exelixis
ExScientia
Eyevance
Fairview Health System
FasTrack Pharmaceuticals
Ferozsons Laboratories
Ferring Pharmaceuticals
Fibrocell Science
Foghorn Therapeutics
Forest Laboratories
Fosun Pharmaceutical
Fox Chase Chemical Diversity Center
Fresenius Kabi Pharmaceuticals
FSD Pharma
Fusion Pharmaceuticals
FusionVax
Galapagos
Galmed Pharmaceuticals
GE Healthcare
Genentech
Generex Biotechnology
Genevant Sciences
Genexine
Genfit
Genmab
Gentium
Genzyme
Geron
Gilead Sciences
Glaukos
Glenmark Generics Inc USA
Glenmark Pharmaceuticals
Goldfinch Bio
Government of Israel
GPCR Therapeutics
Gravocore
Grifols
GSK
GT Biopharma
Hai Kang Life
Hail First Pharma
Hainan Sihuan Pharmaceutical
Halo Labs
Halozyme Therapeutics
Hansen Medical
Health Canada
Healthcare Royalty Partners
Health Discovery
Heartseed
Heat Biologics
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HekaBio
Helsinn Therapeutics
HemoCleanse
Hemogenyx
HemPup
Henlius Biotech
Hetero Labs
HIBM Research Group
Hikma Pharmaceuticals
Hoffmann La Roche
Hollister Biosciences
Hookipa Pharma
Horizon Pharma Inc
Huadong Medicine
HyperGenomics
I-mab
Icahn School of Medicine at Mount Sinai
Ice + Jam
Iconovo
IDC-GP Pharm
IDEAYA Biosciences
Idera Pharmaceuticals
Idorsia
Idun Pharmaceuticals
IGM Biosciences
iMetabolic Biopharma
Immugenyx
Immunic
ImmunityBio
Immunomedics
Immunomic Therapeutics
Immunovative Therapies
ImmVira
Impax Laboratories
Imprimis Pharmaceuticals
In4Derm
iNAP
Incannex Healthcare
Incuron
Incyte
Indiana University
Infinity Pharmaceuticals
InflaRx
Inhibitor Therapeutics
Innate Pharma
Innocoll
Innovate Biopharmaceuticals
Innovation Pharmaceuticals
Innovent Biologics
Innovet
Innovus Pharmaceuticals
INO Therapeutics
Inspiration Biopharmaceuticals
Instrumentation Laboratory
IntelGenx
Intellia Therapeutics
IntelliCell BioSciences
Intellikine
Internet Marketing Consortium
Intrexon
Intuitive Surgical
Invekra
Inverness Medical Innovations
Ionis Pharmaceuticals
Ipsen
Iroko Pharmaceuticals
Ironwood Pharmaceuticals
Israeli National Authority for Technological Innovation
Itrom Pharmaceutical Group
Ivantis
Jaguar Health
Janssen Biotech
Janssen Pharmaceuticals
Jazz Pharmaceuticals
JFC Technologies
Jiangsu Alphamab
Jiangsu Lianhuan Pharmaceuticals
Jiangsu NHWA Pharmaceutical
Ji Xing Pharmaceuticals
John Morley Foods
Joincare Pharmaceutical
Journey Medical
Jubilant Life Sciences
Jumpcan Pharmaceutical
Juniper Pharmaceuticals
Junshi Biosciences
Jupiter Wellness
Juventas Therapeutics
K2M
Kadmon Pharmaceuticals
Kaken Pharmaceutical
Kalbe Genexine Biologics
KaloBios Pharmaceuticals
Karveer Meditech
KemPharm
Kensey Nash
Kieran Murphy
Kinetic Concepts
Kiniksa Pharmaceuticals
Kintor
Kiromic Biopharma
Kite Pharma
Kitov Pharma
Klaria
Klinge Biopharma
Knighton Foods
Knight Therapeutics
Kodiak Sciences
Kowa
Kraig Biocraft Laboratories
KVK-Tech
Kwang Dong Pharmaceutical
Kymera Therapeutics
Kyowa Hakko Kirin
Kyverna Therapeutics
L1 Systems
Laboratories Acbel
Lantheus Holding
Launch Therapeutics
Lee Moffitt Cancer Center
Legend Biotech
LegoChem Biosciences
Level Brands
LFB Biotechnologies
Lifestyle Delivery Systems
Ligand Pharmaceuticals
Lineage Cell Therapeutics
Link Health
Lipidor
Lipocine
Lixte Biotechnology
Lorna Linda University
Lotus Pharmaceuticals
Loxo Oncology
Lubrizol
Lumenis
Lundbeck
Lung Therapeutics
MabCure
Macrogenics
Magenta Therapeutics
MainPointe
Mallinckrodt Pharmaceuticals
Marvanal
Marv Enterprises
Massachusetts General Hospital
Matrix Biomed
Mayne Pharma
McComb Foundation
McEwen Centre for Regenerative Medicine
Meda
Medica
Medica Avante
Medical Technologies Innovation Asia
Medice Arzneimittel Putter
Medicines Patent Pool Foundation
Medicox
MediGene
Medigus
MedImmune
Medison Pharma
Medivation
Medivir
Medovex
MEI Pharma
Melmed
Memory Dx
Mercer University
Merck and Co
Merck KGaA
Merck Serono
Merus
Methodist Hospital Houston
Micromet
Mikah Pharma
Millennium
Mimi's Rock
Mindset Pharma
Ministry of Health
Labor and Welfare
MiNK Therapeutics
Miraculins
Miralogx
Mira Pharmaceuticals
Miromatrix Medical
Mitsubishi Tanabe Pharma
Moderna
Modis Therapeutics
Moleculin Biotech
Mologen
Momenta Pharmaceuticals
Monash University
Monopar Therapeutics
Morgan Stanley
MorphoSys
Mount Sinai Health System
MultiCell Immunotherapeutics
Munich Leukemia Laboratory
Mylan Laboratories
Mylan Pharmaceuticals
Myovant Sciences
NanoVibronix
NanoViricides
NantCell
NantKwest
Nantong Jinghua Pharmaceutical
NantWorks
Napo Pharmaceuticals
Natac Biotech
Natco Pharmaceuticals
National Green Biomed
Nektar Therapeutics
Neogenomics
Neotope
Nephrogenex
Nephros
Nestle Health Science
Neuraxpharm
Neurocrine Biosciences
NeuroRx
NeuroSigma
NeuroVive Pharmaceutical
NeuroVive Pharmaceutical Asia
NewLeaf Brands
Newsoara Biopharma
New York University
NexMed
NextCure
Nextleaf Solutions
Nexvet
NGM Biopharmaceuticals
Nicox
Nkarta Therapeutics
NLS Pharmaceutics
Nordic Bioscience
Norgine
NorthStar Medical Radioisotopes
Notable Labs
Novadaq Technologies
NovaDel Pharma
Novan
Novan Therapeutics
Novartis
Novartis Vaccines and Diagnostics
Novocure
Novo Nordisk
Novus Biologicals
NRx Pharmaceuticals
Nucorion
Numab
Nunzi Pharmaceutical
Nurix Therapeutics
Nutech Medical
NutraOrigin
NXTGEN
Nymox Pharmaceutical
Oberland Capital
Ocugen
Oculus Innovative Sciences
Ocumension Therapeutics
Omeros
Oncologie
Oncolytics Biotech
OncoMed Pharmaceuticals
Onconova Therapeutics
Onegevity
One Way Liver Genomics (OWL)
ONK Therapeutics
Ono Pharmaceutical
Onxeo
Onyx Pharmaceuticals
Opexa Therapeutics
Opthea
OptiBiotix
OptiNose
Oragenics
Oramed Pharmaceuticals
Orexigen Therapeutics
Organovo
Orgenesis
Orion
Orox Pharmaceuticals
OrthoCyte
Otsuka
OvaMed
Ovid Therapeutics
Oxford BioMedica
Oxis Biotech
Oxygen Biotherapeutics
OxySure Systems
Oyster Point Pharma
Pan-Provincial Vaccine Enterprise
Parnell Pharmaceuticals
Par Pharmaceutical
PDL BioPharma
PDS Biotechnology
Penwest Pharmaceuticals
Pernix Therapeutics
Perugia University
Pfenex
Pfizer
Pharmacyclics
PharmaCyte Biotech
PharmaMar
PharmaNova
Pharmastrip
Philogen
Phosphagenics
Photocure ASA
Phusion Laboratoies
Phyto Nutricare
Pipex Pharmaceuticals
Plandai Biotechnology
Pluristem Therapeutics
POINT Biopharma
Portola Pharmaceuticals
Poseida Therapeutics
Pozen
PreMD
Premier Biomedical
Professional Compounding Centers of America
Progenics Pharmaceuticals
Prometic Life Sciences
ProQR Therapeutics
Prosidion
Protagonist Therapeutics
Protalix BioTherapeutics
Proteonomix
Prothena
ProtoKinetix
Pulmatrix
Puma Biotechnology
QED Therapeutics
QRxPharma
Quick Med Technologies
Quigley Corporation
Quoin Pharmaceuticals
Rayner Surgical
Reata Pharmaceuticals
Recordati
Recro Pharma
RedHill Biopharma
Reedy Creek Investments
RegenaStem
Regeneron Pharmaceuticals
Regenxbio
Regnum
Relay Therapeutics
Relief Therapeutics
Relmada Therapeutics
RenalytixAI
ReNeuron
Repare Therapeutics
Replicel Life Sciences
Repligen
Reprise Biomedical
Resarci Therapeutics
Retrophin
rEVO Biologics
Revolution Medicines
Rigel Pharmaceuticals
RNL Bio
Roche
Rockefeller University
Roivant Sciences
Royalty Pharma
RST Biomedikal Sanayi
Ruthigen
RXi Pharmaceuticals
S2 Therapeutics
SACCO
Sagard Healthcare Royalty Partners
Sage Therapeutics
Salix Pharmaceuticals
Sam Amer
Sanara MedTech
Sandoz
Sanofi
Sanofi-Aventis
Sanofi-Pasteur
Sanpellegrino Cosmetics
Santarus
Santen Pharmaceutical
Sanuwave Health
SA Pathology
Sapientia Pharmaceuticals
Sarepta Therapeutics
Schrodinger
Scopus BioPharma
Seagen
Seattle Genetics
Seelos Therapeutics
Sekris Biomedical
Senetek
Senior Paradise
Sensory Cloud
Seqirus
Seres Therapeutics
Sermonix Pharmaceutical
Sesen Bio
SevenScore Pharmaceuticals
Shanghai Pharmaceuticals Holdings
Sheba Medical Center
Shenzhen BioScien Pharmaceuticals
Shield Therapeutics
Shionogi
Shire Pharmaceuticals
Shore Therapeutics
Siemens Healthcare Diagnostics
Sigma-Tau
Sinclair Pharmaceuticals
Sinobiopharma
Sinopharm
Sio Gene Therapies
Skinvera
Skyline Diagnostics
Solarvest BioEnergy
Soliance
Soligenix
Sonoma BioTherapeutics
Sorrento Therapeutics
Spectranetics
Spencer Pharmaceutical
Spinal USA
St. Jude Children's Research Hospital
STADA Arzneimittel
Staidson (Beijing) BioPharmaceuticals
Stanford University
Stealth BioTherapeutics
Stellar Biotechnologies
St Jude Medical
Stoke Therapeutics
Strongbridge Biopharma
Sucampo AG
SUDA Pharmaceuticals
Sumitomo Dainippon Pharma
Sunesis Pharmaceuticals
Sunovion Pharmaceuticals
Sun Pharmaceutical
SuperNova Diagnostics
Sutro Biopharma
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbollon
Syndax Pharmaceuticals
Synergy Strips
Syntopix
Tactical Relief
Taiba
TaiGen Biotechnology
Taiho
Takeda Pharmaceutical
Talaris Therapeutics
Tango Therapeutics
Target Group
Tauriga Sciences
TB Alliance
TearLab
Technion Research and Development Foundation
Teijin
Telomir Pharmaceuticals
Tesaro
Tetra Bio-Pharma
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
Texas A&M University
Texas Heart Institute
TFF Pharmaceuticals
TG Therapeutics
Therakine
TherapeuticsMD
Theravance
Theravance Biopharma
The Regents of the University of California
Thorne Research
Threshold Pharmaceuticals
TiGenix
Tilray
Titterington Veterinary Services
Tiziana Life Sciences
Tocagen
TONIX Pharmaceuticals
Torii Pharmaceutical
TRACON Pharmaceuticals
Tramorgan
Transgene
Travere Therapeutics
Trellis Bioscience
Trevena
Trimedyne
Trimeris
TrovaGene
TTFactor
Tufts University
Turnstone Biologics
Tyme Technologies
Ultragenyx Pharmaceuticals
Uluru
Unigene Laboratories
UniQure
Universal Cells
University College Dublin
University Health Network
University of Alberta
University of California
University of Central Florida Research Foundation
University of Colorado
University of Florida Research Foundation
University of Geneva
University of Louisville
University of Missouri
University of Notre of Dame
University of Pennsylvania
University of Texas
University of Virginia
University of Western Sydney
University of Zurich
UOP
Uppsalagruppen Medical
Upstream Peripheral Technologies
UroGen Pharma
Valeant Pharmaceuticals
ValiPharma
Valneva
Valor Biotherapeutics
Vanderbilt University
Vasomune Therapeutics
Vaxent
VBL Therapeutics
Veloxis Pharmaceuticals
Veracyte
Verenium
Verity Pharmaceuticals
VeroScience
Vertex Pharmaceuticals
Vida Concepts
Vifor Pharma
ViiV Healthcare
Virbac
Viropharma
VistaGen Therapeutics
Vividion Therapeutics
Vivus
VolitionRX
Voronoi
Voyager Therapeutics
Vyera Pharmaceuticals
VYNE Therapeutics
Vyrix Pharmaceuticals
Watson Pharmaceuticals
WAVE Life Sciences
Wigen Biomedicine
Wisconsin Alumni Research Foundation
World Class Extractions
WPD Pharmaceuticals
WUGEN
Xbrane Bioscience
Xencor
Xlife Sciences
XPhyto Therapeutics
XTL Biopharmaceuticals
Xynomic Pharmaceuticals
Yale University
Yeda Research and Development Company
Yeugnam University
Yissum Research Development
ZAI Laboratory
Zalicus
Zenitech
Zenith Epigenetics
Ziopharm Oncology
Zogenix
ZS Pharma
Zymeworks
For more information about this report visit
https://www.researchandmarkets.com/r/pilfnx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
疫苗
100 项与 AvidinOx-Lu-177-DOTA-Biotin 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结直肠癌肝转移 | 临床1期 | 奥地利 | 2013-11-11 | |
| 肝癌 | 临床1期 | 奥地利 | 2013-11-11 | |
| 肝癌 | 临床1期 | 意大利 | 2013-11-11 | |
| 肝转移 | 临床1期 | 奥地利 | 2013-11-11 | |
| 肝转移 | 临床1期 | 意大利 | 2013-11-11 | |
| 结直肠癌 | 临床1期 | - | - | |
| 淋巴瘤 | 临床1期 | - | - | |
| 恶性腹水 | 临床前 | 意大利 | - | |
| 恶性腹水 | 临床前 | 瑞士 | - | |
| 恶性腹水 | 临床前 | 奥地利 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
No Data | |||||||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用